• Vivos Therapeutics dismissed auditor Baker Tilly effective Sept. 29, 2026.
• Haynie & Company engaged to audit the year ending Dec. 31, 2026.
• Audit opinions for 2025 and 2024 carried going-concern warnings; no adverse or disclaimer opinions.
• No reported disputes with Baker Tilly on accounting, disclosure, or audit scope during 2024-2025 through dismissal.
• Haynie held limited August 2026 discussions on a proposed joint venture; no accounting conclusion issued; transaction not completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045193), on October 01, 2026, and is solely responsible for the information contained therein.